GlassScriptPhysician profile
Gary J Fishbein
NPI 1184626384
$68,658.08
in general payments reported to CMS, 2019-2025
25 companies · $4,755 in 2025
The $4,755 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $9,182 · 2021: $7,898 · 2022: $1,618 · 2023: $12K · 2024: $7,281 · 2025: $4,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,065 · Consulting Fee: $8,500 · Food and Beverage: $6,196 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,064.97 |
| Consulting Fee | $8,500.00 |
| Food and Beverage | $6,196.10 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19,548.17 | 2019-2025 | Avvigo Guidance System, General - Vascular Intervention, Eluvia |
| Esperion Therapeutics, INC. | $12,365.55 | 2020-2021 | |
| Amgen INC. | $11,055.09 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $5,011.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $4,839.57 | 2019 | |
| Avinger INC. | $4,407.80 | 2019-2023 | Pantheris |
| Cagent Vascular INC | $2,706.76 | 2025 | Serrantor |
| Abbott Laboratories | $1,975.59 | 2019-2024 | Perclose Proglide, Supera, Perclose Prostyle |
| Janssen Research & Development, LLC | $1,221.26 | 2023 | |
| Philips North America LLC | $1,148.47 | 2022-2025 | Igt Devices Undivided, IV Other, (4066) Tack Endovascular Systems Atk |
| Merck Sharp & Dohme LLC | $1,131.68 | 2023 | |
| Novartis Pharmaceuticals Corporation | $1,090.70 | 2023 | Leqvio |
| Abiomed | $810.84 | 2021-2024 | Impella |
| Medtronic Vascular, INC. | $249.03 | 2019 | |
| Shockwave Medical, INC | $221.47 | 2019-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $150.10 | 2025 | Torus Stent Graft System, Endocross Device |
| W. L. Gore & Associates, INC. | $139.96 | 2025 | Gore Viabahn Vbx Balloon Expandable Endo |
| Reflow Medical INC | $138.99 | 2025 | |
| Cardiva Medical, INC. | $135.37 | 2019-2023 | Cardiva Vascade 6/7f Vcs |
| E.R. Squibb & Sons, L.L.C. | $131.70 | 2025 | |
| Penumbra, INC. | $84.26 | 2023 | Indigo System |
| Medtronic, INC. | $54.76 | 2021 | |
| Chiesi USA, INC. | $23.96 | 2019 | |
| Biotronik INC. | $15.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Fishbein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.